APOE Genotype Registry for Alzheimer's Prevention in France

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

ALZEVIT is a decentralized, digital-first observational cohort in France that aims to build a large APOE genotyping registry and a trial-ready infrastructure for precision prevention of Alzheimer's disease. Participants provide electronic consent and self-collect saliva samples at home for centralized APOE genotyping, with data stored in a GDPR-compliant registry. The first phase plans to enroll 50,000 individuals aged 45+ to map APOE genotype distribution and enable risk stratification for targeted prevention efforts in the context of emerging disease-modifying therapies. The study integrates digital tools, centralized genetics, and longitudinal phenotyping across French memory centers to identify high-risk individuals, particularly APOE ε4 carriers and ε4/ε4 homozygotes, for future prevention trials. Interventions are not part of this observational phase, but the infrastructure supports future trial readiness.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants who sign the electronic Informed Consent form.
* Adults aged over 45 years old (inclusive) at the time of consent.
* Participants residing in France.
* Participants able to read and understand the study information in French or with the help of a legal representative.
* Participants are capable of electronically signing the consent form.
* Participants affiliated with the French national health insurance system.
* Participants with access to the internet and a valid email address.
* Participants can self-collect and return a saliva sample using a provided kit (ORAcollect® Dx device).

Exclusion Criteria:

* Participants who do not sign the Informed Consent form.
* Participants who are unable to read or understand French.
* Participants younger than 45 years at the time of consent.
* Participants with known cognitive impairments, severe dementia, or psychiatric conditions that prevent informed consent.
* Participants with a documented substance use disorder (alcohol or drug dependence) within the past 24 months.
* Participants who cannot be reliably contacted by email or phone.
* Participants previously enrolled in the ALZEVIT study or its pilot phase.
* Participants who are legally protected adults or under guardianship, curatorship, or judicial/administrative custody.
* Participants whose physical condition does not allow them to perform the tasks required by the study.
* Participants who, in the judgment of the Investigator, are unlikely to comply with study procedures.
* Participants who are study staff (investigators, sub-investigators, coordinators, assistants) or their immediate family members.
* Participants who are incarcerated or deprived of liberty by judicial or administrative decision.
* Participants with any disease or condition that, in the opinion of the Investigator, would compromise participation or safety.

Where it's running

• FIRALIS SA - Centre de Prélèvements Biologiques
  Huningue, France Recruiting

Study contacts

• Principal investigator: Audrey GABELLE,, MD, PhD — CMRR Languedoc-Roussillon - Montpellier
• Study coordinator: Hüseyin FIRAT, MD, PhD, HDR
• Email: hueseyin.firat@firalis.com
• Phone: +33 (0) 389 911 321

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Restoring Cervical Lymphatic Drainage in Alzheimer’s Disease

  A small study tests whether a minimally invasive surgery to improve cervical lymphatic drainage can affect biomarkers, brain imaging, and cognition in people with Alzheimer's who can’t access other disease-modifying therapies.

  Recruiting University of Siena · Siena, Tuscany · NCT07854327

• Low-Dose Radiation Therapy to See if It Helps Alzheimer's and Inflammatory Dementias

  Researchers will test whether giving small amounts of whole-brain radiation over a short course, then monthly boosts for a year, is tolerable and safe in people over 50 with Alzheimer's or dementia with inflammatory features.

  Recruiting Phase 1/2 Renaissance Institute of Precision Oncology and Radiosurgery · Winter Park, Florida · NCT07693140

• Acoustic Stimulation During Sleep for Alzheimer’s Disease

  Researchers test whether playing gentle sounds during sleep can help people with Alzheimer’s disease see if their thinking improves compared with a sham sound.

  Recruiting Xuanwu Hospital, Beijing · Beijing · NCT07924657

• FAME: A Italian test to recognize famous faces and name them

  This project tests an Italian battery to see how well people with stroke or neurodegenerative diseases recognize famous faces and recall their names, familiarity, and related facts.

  Recruiting at 8 sites Istituti Clinici Scientifici Maugeri SpA · Sciacca, AG and 9 other locations · NCT07911878

• NMS-01 safety test in people with mild to moderate Alzheimer's disease

  This pilot test checks whether the focused ultrasound device NMS-01 is safe and can briefly open the blood-brain barrier in adults with mild-to-moderate Alzheimer's disease.

  Recruiting Neumous Inc. · Seoul, Seodaemun · NCT07869238

• Choose Myself (Before) Losing Myself

  We’re testing an educational interactive booklet to help people with dementia or memory problems think about future medical decisions and start conversations with family or caregivers.

  Recruiting The Cleveland Clinic · Cleveland, Ohio · NCT07846566

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.